Our Centres
Our four major platforms are established to integrate research with clinical care and to accelerate the collection and analyses of high-throughput clinical and biological data required for our epidemiologists, computational scientists, clinical and basic science researchers to enable a better understanding of disease mechanisms. These platforms seek to meet the need for reproducible data and to achieve the goals of increasing external peer-reviewed funding and success in large-scale team grant competitions. The platforms will also enhance our productivity by collaborating as one team. The outcomes from projects at these centres are a better basic understanding of the diseases, new diagnostic tests, and improved therapies, all ultimately focused on improved patient care. To enable this, our cross-cutting centres and platforms include:
This centre will provide platforms to all the arthritis investigators for high throughput data to maximize the potential of our biobanks for a basic understanding of the disease for biomarker and therapeutic target discovery. Services provided in this centre include Next Generation Sequencing (RNA, microRNA, single cell Seq), metabolomics, multiplexing, etc. This centre will also be a key resource for our partner institutes at TWH, the Krembil Brain Institute and the Donald K. Johnson Eye Institute.
This centre will utilize artificial intelligence and advanced bioinformatics to identify biomarkers and predictive algorithms for surgical and medical treatments for arthritis. The centre will also apply advanced bioinformatics for modelling disease mechanisms and defining novel therapeutic targets. The analytics, diagnostics, therapeutics, and translational medicine platforms are all anchored in accurate disease phenotyping, based on longitudinal observation cohorts.
This Centre will focus on responding to the needs of the population with musculoskeletal diseases including autoimmune rheumatic, bone, joint, and spine conditions at the population level. This includes identifying at-risk groups for existing and novel targeted interventions and implementation strategies to bring proven interventions into clinical practice. We will translate these interventions by creating, testing, and implementing new models of care.
This centre will focus on stem cells (manufacturing and testing), biologics, tissue engineering and other novel therapeutics and interventions. It will facilitate and expand our capacity to conduct clinical research and trials.
